Anzeige
Mehr »
Login
Sonntag, 28.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Fokus auf Nurexone: High-Level Biotech im Pennystock-Kleid!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
46 Leser
Artikel bewerten:
(0)

AdvaMed 2013: The MedTech Conference Opens Monday in Washington, D.C.

WASHINGTON, Sept. 22, 2013 /PRNewswire-USNewswire/ --AdvaMed 2013: The MedTech Conference, the medical technology industry's premier gathering, opens Monday at the Walter E. Washington Convention Center in Washington, D.C. More than 2,000 attendees representing approximately 1,000 medical device and diagnostics companies will discuss the key regulatory, reimbursement, legal, compliance and business issues impacting the industry.

This year's conference explores the theme, Bringing the Value of Innovation to Patient Care, Health Care Systems and Economies Worldwide, and attendees will learn how medical technology not only provides patients with life changing innovations, but generates efficiencies and cost savings for health care systems while creating good-paying, high-tech jobs. Between 1980 and 2010, advanced medical technology helped cut the number of days people spent in hospitals by more than half. In that same time span, medical advancements helped add five years to U.S. life expectancy and reduce fatalities from heart disease and stroke by more than half.

"This is an exciting time for medical technology industry, with tremendous breakthroughs that are transforming patient care," said Stephen J. Ubl, president and CEO of the Advanced Medical Technology Association (AdvaMed). "If you want to learn about the opportunities and challenges facing the industry today and how we're working to increase the value we provide to patients, health care systems and economies, AdvaMed 2013 is the place to be."

Programming on Monday includes a "CEOs Unplugged" session on regulatory developments in the European Union, and educational panel sessions address a range of subjects, including emerging and early growth company issues, business development and finance, compliance best practices and eHealth/Health IT & mHealth/telemedicine.

Additionally, the Medical Technology Veterans Program (MVP) Boot Camp for Returning Heroes begins on Monday. Through this initiative, returning veterans will receive career building skills and networking opportunities to help them pursue employment opportunities in the medical technology industry. Also beginning Monday is the Association's Scientist Mentoring and Diversity Program, which pairs minority scholars with industry mentors for a one-year program to help further their MedTech careers.

For a full conference agenda, visit www.advamed2013.com.

About AdvaMed 2013: The MedTech Conference
AdvaMed 2013: The MedTech Conference is the leading gathering in North America of global MedTech executives with regulatory, reimbursement, business development, legal, IP, marketing, quality, compliance, and other key responsibilities. Along with industry leaders, the conference attracts business development professionals, investors, policy-makers, members of the media, legal experts, consultants, distributors, and other important stakeholders will attend this international conference.

More than 2,000 attendees will network, conduct business, gain access to capital and share insights in Washington, D.C. from September 23-25. The conference also features world-class plenary speakers, networking and business development opportunities. Visit http://advamed2013.com, follow @AdvaMed2013 on Twitter, or join the AdvaMed 2013 LinkedIn group to learn more.

SOURCE AdvaMed 2013

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2013 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.